


Democratic Republic of the Congo

Region: Central Africa

Key information on co-financing

- Gross National Income per capita (2017): \$ 450
- Co-financing status (2019): Initial self-financing
- Country is projected to stay in initial self financing phase for next 5 years.




Immunisation financing

	2013	2014	2015	2016	2017
Vaccines used in routine immunisation					
- Government expenditure	\$ 3,727,193	\$ 2,628,012	\$ 2,370,993	\$ 3,775,045	\$ -
- Total expenditure	\$ 53,946,231	\$ 59,020,935	\$ 66,955,379	\$ 58,763,460	\$ 63,639,109
- Government as % of total	7%	4%	4%	6%	0%
Routine immunisation					
- Government expenditure	\$ 4,999,802	\$ 3,845,799	\$ 3,158,375	\$ 3,934,332	\$ 633,902
- Total expenditure	\$ 75,077,165	\$ 79,543,362	\$ 115,874,072	\$ 102,927,251	\$ 75,792,143
- Government as % of total	7%	5%	3%	4%	1%

Source: WHO-UNICEF Joint Reporting Form 2017

Domestic General government expenditure on health as a share of gross domestic product: **1%**

Expenditure on routine immunisation in 2017



Source: WHO National Health Accounts, 2015

Gavi supported vaccines

Vaccines	Type	Year(s) of Gavi support	Co-financing required
Yellow Fever	Routine	2004-present	Yes
Tetra DTP-HepB	Routine	2007-2008	No
Pentavalent	Routine	2008-present	Yes
PCV	Routine	2011-present	Yes
Measles SIA	Campaign	2013-2014, 2016-2017	No
IPV	Routine	2015-present	No
Meningitis A	Campaign	2016	No

Co-financing payments


Year	Total amount paid by the country	Co-financed vaccines		
		Vaccine	Type	Amount
2009	\$ 943,000	Penta	Yellow Fever	-
2010	\$ 1,229,000	Penta	Yellow Fever	-
2011	\$ 2,251,000	Penta	Yellow Fever	PCV
2012	\$ 2,864,000	Penta	Yellow Fever	PCV
2013	\$ 2,000,000	Penta	Yellow Fever	PCV
2014	\$ 6,570,000	Penta	Yellow Fever	PCV
2015	\$ 7,937,000	Penta	Yellow Fever	PCV
2016	\$ 10,040,000	Penta	Yellow Fever	PCV
2017	*	Penta	Yellow Fever	PCV
2018	\$ 6,260,000	Penta	Yellow Fever	PCV

*Country opted for a payment plan for 2017 co-financing.

Co-financing obligations for 2019

	Co-financing obligations (in US\$)	Co-financing obligations (in doses)
Pentavalent	\$ 2,646,500	3,720,500
YF	\$ 1,607,000	1,315,600
PCV	\$ 3,021,000	1,011,600
Total	\$ 7,274,500	

Co-financing projections for 2020 - 2024



	2020	2021	2022	2023	2024
Penta	\$ 1,817,455	\$ 1,897,237	\$ 1,962,919	\$ 2,030,013	\$ 2,098,502
PCV	\$ 1,613,900	\$ 1,684,746	\$ 1,743,072	\$ 1,802,651	\$ 1,863,470
Rota	\$ 495,886	\$ 564,653	\$ 674,686	\$ 705,668	\$ 754,894
YF routine	\$ 601,273	\$ 627,114	\$ 648,379	\$ 670,093	\$ 692,251
Total	\$ 4,528,515	\$ 4,773,751	\$ 5,029,057	\$ 5,208,425	\$ 5,409,117

- Projections are based on Gavi's operational forecast version 16.
- These projections do not guarantee renewal of support or approval of country's application.
- Final co-financing obligations will be communicated through decision letters.